A DNA test that can detect how well a patient metabolises commonly prescribed medications could save New Zealand millions and improve health outcomes. A middle-aged man taking a statin to lower his cholesterol had tried to tell his doctor the medication was giving him aches and pains. It turns out the man has an elevated risk of muscle-related side effects from that particular statin.
A woman who travels a lot for work has been taking increasing doses of melatonin to cope with the time zone changes. It’s emerged she is a non-responder metaboliser for this medication – meaning it won’t have a noticeable effect at any dose, because it is being removed from her body too quickly.
These are the kind of findings Pinnacle Ventures is helping patients and their healthcare professionals make as it develops a ground-breaking test showing how a person’s genetic factors influence their response to medications.